Several large U.S. states are not heeding new federal health officials’ calls to reduce Covid-19 testing of some exposed to the virus, joining a broad rebuke of the Trump administration by public health leaders.
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering.
German biotech firm BioNTech and U.S. drugmaker Pfizer reported additional data showing their experimental Covid-19 vaccine was safe and induced an immune response in patients.
Unlisted German biotech firm CureVac will become the second company after rival BioNTech to launch human trials of an experimental coronavirus vaccine in the country, eyeing a potential approval in mid-2021.
As AstraZeneca closes in on developing a vaccine against COVID-19, the U.K. pharma giant struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of the preventative medication by the end of 2020.
The European Union urged the United States to reconsider its decision to cut ties with the World Health Organization over its handling of the coronavirus pandemic
Global coronavirus cases surpassed 5 million, with Latin America overtaking the United States and Europe in the past week to report the largest portion of new daily cases globally.
Any vaccine to fight the new coronavirus will not be ready for use for at least two years, the chief executive of Swiss pharmaceutical company Novartis – which no longer makes vaccines itself – told a German newspaper.
A review of some recently published scientific studies, including researchers at the University of Maryland Baltimore County identifying a single nucleotide that controls two forms of the HIV virus’ RNA.
Pfizer aims to make 10-20 million doses of a coronavirus vaccine the company is developing with Germany’s BioNtech by the end of 2020 for emergency use depending on trial results, the U.S. drugmaker’s vaccines head said.
